Target and Im-Oncology Therapeutic Approaches for Lung Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: closed (25 April 2023) | Viewed by 37548
Special Issue Editors
Interests: lung cancer; targeted therapy; Im-oncology therapy
Special Issue Information
Dear Colleagues,
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1.8 million people are diagnosed with lung cancer, and 1.6 million people die as a result of the disease. Five-year survival rates vary from 4 to 17% depending on stage and regional differences.
Recognition that lung cancer is primarily a disease of the genome has fueled recent focus on the development of more personalized or precision treatments based on genomic information. Lung cancer can thus be subdivided into clinically relevant molecular subsets, including EGFR, ALK, ROS1, HER2, BRAF, KRAS, RET, MET, and so on. Targeted therapy could lead to substantial outcome improvements. Meanwhile, unprecedented advances have been made in lung cancer treatment with the use of immunotherapy. However, limited responses to a subset of patients, drug resistance, and treatment-related adverse events are still unsolved. The scope of this Special Issue is to provide an overview of recent advances in the field of targeted therapy and immunotherapy for lung cancer. Therefore, researchers in this field are encouraged to submit an original article or review to this Special Issue (case reports and short reviews are not accepted).
Prof. Dr. Shun Lu
Prof. Dr. Yongfeng Yu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- targeted therapy
- immunotherapy
- drug resistance
- biomarkers
- adverse events
- tumor heterogeneity
- immune microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.